US FDA gives nod to use of Eli Lilly's new COVID antibody treatment

Previously the drug was authorized for high-risk patients with confirmed COVID-19.

Published: 17th September 2021 03:01 PM  |   Last Updated: 17th September 2021 03:01 PM   |  A+A-

People walk through the food truck area on the opening day of the Oklahoma State Fair. (Photo | AP)


WASHINGTON US health officials have authorised Eli Lilly's COVID-19 treatment for a new use in preventing disease in people who have been recently exposed to the virus.

The Food and Drug Administration on Thursday granted emergency use of the drug for adults and children older than 12 who may have an infection and are at high-risk for getting severe COVID-19.

Previously the drug was authorized for high-risk patients with confirmed COVID-19.

Earlier this summer the FDA authorised preventative use for a similar antibody drug from competitor Regeneron Pharmaceuticals.

Antibody drugs are one of the only treatments proven to reduce the risk of death from COVID-19, especially for people who are not yet in the hospital.

Demand for the drugs has boomed as the delta variant sends cases surging again across the U.S. Federal officials have reported a 20-fold increase in orders for the drugs since mid-July.


Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on are those of the comment writers alone. They do not represent the views or opinions of or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp